InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$218.01

2026-10-16

Market Cap

$87.0B

Volume

21.3M

52-Wk High

$242.29

52-Wk Low

$22.28

Trailing PE

-27.3

P/S

39.07

Gross Margin

-12.6%

Net Margin

-141.4%

ROE

-39%

ROIC

-39%

Piotroski

2/9

Altman Z

12.7

1-Yr Return

+758.6%

5-Yr Return

+1441.8%

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

SectorHealthcareIndustryBiotechnologyExchangeNASDAQMarket Cap$87.0BEmployees4,700 (SEC-filed)CEOStÃ©phane BancelIPO2018-12-07CountryUS

325 Binney Street, Cambridge, MA 02142 · Tel 617 714 6500 · modernatx.com

INSIDERSTREET SCORE30 / 100Street mean $126.82 (11 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$73M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · MRNA +758.6% · S&P 500 +15.9% · spread +742.8pp

7 Years vs S&P 500 · MRNA +1441.8% · S&P 500 +189.9% · spread +1251.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE30of 100

Score Breakdown

Profitability	11/100
Growth	24/100
Momentum	30/100
Quality	41/100
Earnings Quality	41/100
Balance Sheet	0/100
Value	36/100
Risk (safety)	100/100
Overall	29.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
REGN	68
VRTX	76
ARGX	74
ONC	78
ALNY	68
ROIV	38
MRNA	30

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 40 in 24 Q4, latest 30 — -10 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY30 / 100IS Score 29.6 / 100 · -9.9 from peak of 40

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 82 / 100 · Power +64 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 30, price structure 82 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 29.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 21 → 33 → 32 → 30	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 953 → now 784	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)3 buys2026-09-11

Insider Buys (180d)0none disclosed

ETF Funds (30d)950 up / 642 downnet +308 funds

Institutions Added (13F)59managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 953 · latest 784 (-169 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	784	324.8M	$22.3B	82.0%
2026 Q1	725	308.2M	$15.5B	77.8%
2025 Q4	674	304.3M	$8.9B	76.8%
2025 Q3	642	275.1M	$7.1B	69.5%
2025 Q2	670	291.9M	$8.0B	73.7%
2025 Q1	692	282.2M	$8.0B	71.2%
2024 Q4	744	277.2M	$12.1B	70.0%
2024 Q3	788	261.4M	$17.3B	66.0%
2024 Q2	953	262.1M	$30.9B	66.2%
2024 Q1	903	263.3M	$27.9B	66.5%
2023 Q4	880	256.7M	$25.4B	64.8%
2023 Q3	882	246.8M	$25.3B	62.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Hoge Stephen	President	2026-10-15	SELL	39,145	$8.64M	1,636,565
Hoge Stephen	President	2026-10-14	SELL	38,774	$8.28M	1,599,708
Hoge Stephen	President	2026-10-14	SELL	450	$0.10M	1,599,258
Mock James M	Chief Financial Officer	2026-10-05	EXERCISE	1,454	—	60,829
Mock James M	Chief Financial Officer	2026-10-05	TAX W/H	704	$0.13M	60,125
Mock James M	Chief Financial Officer	2026-10-05	EXERCISE	1,454	—	0
Hoge Stephen	President	2026-09-15	SELL	40,281	$5.88M	1,562,029
Hoge Stephen	President	2026-09-14	SELL	40,294	$5.81M	1,525,858

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	19	888,806	$73.1M	Counted
M — Exercises (paired A/D)	54	968,332	$14.6M	None — mechanics
F — Tax withholding	35	76,607	$6.0M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$73.1M19 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-15	Hoge Stephen	39,145	$8.6M
2026-10-14	Hoge Stephen	39,224	$8.4M
2026-09-15	Hoge Stephen	40,281	$5.9M
2026-09-14	Hoge Stephen	40,294	$5.8M
Trailing 12 mo	19 filings	1,135,701	$86M

Filed	Form	Reporting person	% of class	Shares
2026-08-12	SCHEDULE 13G	Capital World Investors	5.60%	22.3M sh
2026-08-06	SCHEDULE 13G/A	Abigail P. Johnson	13.10%	51.8M sh
2026-07-24	SCHEDULE 13G/A	BAILLIE GIFFORD & CO	4.60%	18.2M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Maria Elvira Salazar	House	SELL	$1,001 - $15,000	2026-09-24	2026-10-08
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-11	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09

House 12-Mo7 trades3 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)725

13F Shares308M77.8% of shares out

New / Closed147 / 81positions, QoQ

Increased / Reduced240 / 199positions, QoQ

Put/Call (13F)1.31option positions

Free Float93.2%372M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Banque Pictet & Cie Sa	2.2M	$414M
Douglas Lane & Associates, Llc	1.2M	$224M
Beau Ventures, Llc	1.0M	$193M
Fny Investment Advisers, Llc	107,610	$21M
Czech National Bank	106,680	$21M
Td Waterhouse Canada Inc.	72,591	$14M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$2.2B
VTI	0.1%	$2.2B
VSMPX	0.1%	$2.2B
VTSAX	0.1%	$2.2B
QQQ	0.4%	$1.9B
VOO	0.1%	$1.9B

13F Filers Holding MRNA — quarterly

Institutional Put/Call — quarterly

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session67.3%2026-10-15

20-Day Avg62.7%50-day 60.6%

TrendRising20d vs 50d

By Market CenterQ: 68% · N: 64% · B: 63%latest session

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Weekly Notional ($B)

Where MRNA Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	9.3M	67 sh
Incr Intelligent Cross Llc	6.7M	70 sh
Sgmt Sigma X2	4.6M	69 sh
Ebxl Level Ats	4.2M	47 sh
Mstx Ms Trajectory Cross (Ats-1)	3.7M	96 sh
Iats Ibkr Ats	3.5M	137 sh

Where a dollar of Moderna, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$1.2B	65%
Rest Of The World	$603M	33%
Europe	$53M	3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

MRNA (live moat model)Peer median: REGN · VRTX · ARGX · ONC · ALNY

Component scores from the live moat model. Peer median illustrative.

Moat score 32/100 — None; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Stéphane Bancel	Chief Executive Officer & Director
Stephen Hoge	President
James Mock	Chief Financial Officer
Shannon Thyme Klinger	Chief Legal Officer & Corporate Secretary

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+26.4%

Next Report2026-11-06

Income QualityN/Mloss-making — OCF ÷ net income not meaningful

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+2107.6%	+6.4%	-63.7%	-53.3%	-39.2%
Gross profit	+1878.4%	-11.0%	-84.0%	-19.5%	-38.0%
Operating income	-1842.3%	-29.2%	-145.0%	-6.9%	-22.1%
Net income	-1733.3%	-31.5%	-156.4%	-24.5%	-20.8%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	17.7	18.9	6.8	3.2	1.9
Cost of revenue	2.6	5.4	4.7	1.5	0.9
Gross profit	15.1	13.5	2.2	1.7	1.1
R&D expense	2.0	3.3	4.8	4.5	3.1
SG&A expense	0.6	1.1	1.5	1.2	1.0
Operating income	13.3	9.4	-4.2	-3.9	-3.1
EBITDA	13.5	9.8	-3.3	-3.4	-2.6
D&A	0.2	0.3	0.6	0.2	0.2
Pretax income	13.3	9.6	-3.9	-3.6	-2.8
Income tax	1.1	1.2	0.8	-0.0	0.1
Net income	12.2	8.4	-4.7	-3.6	-2.8
Diluted EPS ($)	28.29	20.10	-12.34	-9.27	-7.26
Diluted shares (M)	431	416	382	384	389

Operating CF$-2B

CapEx$0B

Free cash flow$-2B

SBC$0B

Buybacks$0B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Shown instead of the usual cash-distribution diagram because operating cash flow was not positive this year — there was no internally generated cash to distribute, so the decision-relevant question is what funded the spending. Sources left, uses right; cash is fungible and the statement does not trace which rupee of borrowing bought which asset, so the band is proportional, not a claim about specific flows. Any residual from FX translation is carried explicitly as Other / FX.

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	3.2	2.9	1.9	2.6
ST investments	6.7	5.7	5.1	3.2
Receivables (net)	1.7	1.1	0.6	0.2
Total current assets	13.4	10.3	8.1	6.5
PP&E (net)	2.1	2.7	3.0	2.9
Goodwill + intangibles	0.0	0.1	0.1	0.0
Total assets	25.9	18.4	14.1	12.3
Accounts payable	0.5	0.5	0.4	0.3
Short-term debt	0.0	0.0	0.0	0.0
Deferred revenue	2.0	0.6	0.2	0.1
Total current liabilities	4.9	3.0	2.2	2.0
Long-term debt	0.0	0.0	0.0	1.2
Total liabilities	6.7	4.6	3.2	3.7
Shareholders' equity	19.1	13.9	10.9	8.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	8.4	(4.7)	(3.6)	(2.8)
D&A	0.3	0.6	0.2	0.2
Stock-based compensation	0.2	0.3	0.4	0.5
Working capital change	(3.5)	(0.1)	(0.1)	0.3
Operating cash flow	5.0	(3.1)	(3.0)	(1.9)
Capital expenditures	(0.4)	(0.7)	(1.1)	(0.2)
Investing cash flow	(5.2)	4.2	1.9	1.9
Buybacks	(3.3)	(1.2)	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	(0.2)	(0.3)	(0.0)	0.5
Financing cash flow	(3.4)	(1.4)	0.1	0.6
Free cash flow	4.6	(3.8)	(4.1)	(2.1)

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	146.1%	50.3%	-28.6%	-28.8%	-28.9%	-39%
ROA	76.2%	33.1%	-21.3%	-21.9%	-21.3%	-28.7%
ROIC	281.8%	78.9%	-51.6%	-67.4%	-50.9%	-39.2%
Gross margin	85.2%	71.3%	31.5%	54.2%	55.3%	-12.6%
Operating margin	75.0%	49.9%	-61.9%	-123.3%	-158.1%	-149.0%
Net margin	68.8%	44.3%	-68.8%	-111.3%	-145.2%	-141.4%
EBITDA margin	76.3%	51.8%	-47.9%	-106.1%	-131.3%	-127.0%
FCF margin	75.2%	24.3%	-56.0%	-126.8%	-105.7%	—
VALUATION
P/E	8.97	8.70	-8.33	-4.50	-4.10	-27.3
P/B	7.74	3.80	2.84	1.47	1.34	12.8
P/S	6.17	3.85	5.75	5.00	5.95	39.07
P/FCF	8.21	15.88	-10.27	-3.95	-5.63	-71.2
EV/EBITDA	7.37	6.44	-9.72	-2.87	-3.01	-30.6
EV/Revenue	5.62	3.39	4.68	3.04	3.95	38.9
Earnings yield	11.1%	11.5%	-12.0%	-22.2%	-24.4%	-3.65%
FCF yield	12.2%	6.3%	-9.7%	-25.3%	-17.8%	-1.41%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.76	2.73	3.42	3.67	3.29	2.29
Quick ratio	1.60	2.54	3.36	3.62	3.22	2.18
Debt / equity	0.06	0.06	0.09	0.07	0.22	0.19
Debt / assets	3.7%	4.6%	6.7%	5.3%	15.5%	11.7%
Net debt / EBITDA	-0.73	-0.88	2.24	1.85	1.52	0.15
Interest coverage	739.06	331.17	-102.74	-149.29	-276.60	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	1.11	0.75	0.31	0.20	0.15	0.20
Receivables turnover	7.77	8.28	6.00	5.12	7.17	21.6
DSO (days)	47	44	61	71	51	17
DPO (days)	22	27	39	115	79	24
Cash conversion cycle	128	98	66	-4	1	33
GROWTH (YoY)
Revenue growth	2107.6%	6.4%	-63.8%	-53.1%	-39.3%	—
Net income growth	1733.3%	-31.5%	-156.4%	24.5%	20.8%	—
EPS growth	1603.3%	-27.1%	-157.8%	22.5%	22.2%	—
FCF growth	580.6%	-65.6%	-183.5%	-6.0%	49.3%	—
PER SHARE ($)
EPS (diluted, TTM)	28.31	20.65	-11.93	-9.25	-7.20	-7.96
Book value / share	32.82	47.22	35.07	28.31	22.07	17.07
Revenue / share	41.15	46.60	17.28	8.31	4.96	5.63
FCF / share	30.94	11.31	-9.68	-10.53	-5.24	-3.09
Cash / share	24.89	24.45	21.78	18.25	14.79	12.97
SHAREHOLDER RETURN & SCORES
Buyback yield	0.8%	4.6%	2.9%	0.0%	0.0%	0.01%
Altman Z-Score	9.64	9.82	6.34	3.85	2.56	12.7
Piotroski F-Score	6	5	4	5	3	2/9
Beneish M-Score	7.84	-2.29	-3.62	-2.07	-3.84	-4.42

Model	Score	Zone	Note
Piotroski F-Score	2 / 9	Weak
Altman Z-Score	12.7	Safe (>2.99)	Safe
Income quality	N/M	Loss-making	OCF ÷ net income not meaningful with negative earnings; OCF itself is the signal
Beneish M-Score	-4.42	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	1.02
Interest burden	1.01
Operating margin	-137.8%
Asset turnover	0.19×
Financial leverage	1.42×
= ROE	-39%

Growth Quality (live)	Value
Revenue stability	0.48
Earnings stability	0.46
Earnings persistence	0.97
Revenue CAGR 3y	-40.5%
EPS CAGR 3y	—
FCF CAGR 3y	—

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.01%

Dividend Yield0.00%none paid

Total Shareholder Return-0.21%cash yield

SBC / Revenue15.7%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
REGN	$81.4B	18.9	14%	30.2%	+9.3%	7/9	+39.1%
VRTX	$126.7B	28.9	24%	33.0%	+10.6%	6/9	+22.3%
ARGX	$51.5B	29.6	47%	29.8%	+242.1%	5/9	-2.2%
ONC	$39.4B	25.6	15%	13.9%	+34.3%	8/9	+16.0%
ALNY	$31.0B	38.0	101%	12.7%	+95.1%	6/9	—
ROIV	$24.2B	-88.2	-6%	—	-67.6%	1/9	—
INCY	$22.9B	13.9	31%	35.0%	+26.9%	8/9	—
UTHR	$22.9B	17.6	19%	42.5%	+2.5%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

29 Analysts

Str Sell (0)Sell (6)Hold (15)Buy (8)Str Buy (0)

Mean Target (qtr)$126.8211 targets

Target vs. Price-41.8%last-quarter mean

Next Report2026-11-06street $-1.09

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$2.10B	$2.20B / $1.96B	$-8.31	$-7.81 / $-10.32	17
FY2027	$2.43B	$2.99B / $1.97B	$-4.74	$-2.90 / $-7.56	17
FY2028	$3.42B	$7.39B / $2.21B	$-2.72	$0.60 / $-5.35	15

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$137.00	-37.2%	1
Last Quarter	$126.82	-41.8%	11
Last Year	$67.18	-69.2%	33
All Time	$117.31	-46.2%	96

Rolling mean of published targets vs. last close $218.01. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C-

DCF

1/5

ROE

1/5

ROA

1/5

Debt/Eq

2/5

P/E

1/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

MRNA +758.6% vs S&P 500 +15.9% — spread +742.8pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$201.18	+16.83	+8.37%	Above
SMA 50	$154.93	+63.08	+40.72%	Above
SMA 200	$75.84	+142.17	+187.46%	Above
EMA 9	$215.24	+2.77	+1.29%	Above
EMA 21	$197.77	+20.24	+10.23%	Above
EMA 50	$162.14	+55.87	+34.46%	Above
EMA 200	$92.90	+125.11	+134.67%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6419 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%73

Volume 20%81

Volatility 10%100

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago91%+9 pts since

12 Weeks Ago18%+82 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$201.18

Price vs SMA 50$154.93

Price vs SMA 200$75.84

EMA 9/21 Cross215.2/197.8

SMA 50/200Golden

ADX DirectionADX 63

Supertrend$179

Parabolic SAR$192

SMA Slope3.200

RSI61.7

Stochastic K/D82/84

StochRSI K/D44/47

Williams %R-41

CCI118

TSI vs Signal34.2

CMO23.3

ROC14.74%

OBV SignalAccum

Chaikin MF0.280

MFI63

Force Index42M

Elder Ray Bull40.19

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 84

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$231.94 / $246.85 / $257.21	S1 / S2	$221.58 / $206.67
Bollinger (20,2)	$168.71 – $233.64	Squeeze	Off
52-wk range	$22.28 – $242.29	Off 52-wk high	-10.0%
ATR (14)	$16.88 (7.7%)	Historical vol	94.1%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+3.4%Jan43%

+4.9%Feb38%

+1.1%Mar50%

+12.2%Apr71%

+4.4%May43%

-2.7%Jun43%

+10.2%Jul71%

-5.2%Aug29%

-1.0%Sep43%

-1.2%Oct43%

+23.0%Nov86%

-2.9%Dec25%

Sample: 7 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	MRNA	S&P 500
Weekly volatility (σ, 1y)	26.24%	1.83%
Best / worst week (1y)	+173.9% / -15.0%	—
Max drawdown (5y, monthly)	-94.2%	—
1-week VaR (95%)	-13.8%	—
Beta (5y)	0.90	1.00

MRNA EQUITY WEATHER (LIVE)PARTLY CLOUDY · +31

Trend+52

Momentum+59

Volume+62

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 548 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+30.6+68.2 vs industry

Trend+52.1+91.6 vs industry

Momentum+58.8+107.3 vs industry

Volume+61.6+100.4 vs industry

Reading	MRNA	Biotechnology n=1,668	Healthcare n=5,272	All US symbols n=70,435
Overall	+30.6	-37.6	-24.0	-20.5
Trend	+52.1	-39.5	-25.6	-21.3
Momentum	+58.8	-48.5	-28.5	-15.8
Volume	+61.6	-38.8	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Stéphane Bancel Chief Executive Officer	$19.9M	56% equity+incentive
Stephen Hoge, M.D. President	$18.1M	67% equity+incentive
James Mock Chief Financial Officer	$5.9M	64% equity+incentive
Shannon Thyme Klinger Chief Legal Officer an	$5.4M	64% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	61
Social	61
Governance	51
Composite ESG	58

Composite ESG Trend

Filed	8-K contents	Items
2026-09-30	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-09-01	Material Agreement; Financial Obligation; Unregistered Equity Sales; O	1.01,2.03,3.02,8.01,9.01
2026-07-31	Earnings Release; Exhibits	2.02,9.01
2026-07-08	Officer/Director Change; Regulation FD; Exhibits	5.02,7.01,9.01
2026-05-01	Earnings Release; Exhibits	2.02,9.01
2026-03-05	Entry into Material Definitive Agreement	1.01
2026-02-13	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-02-11	Regulation FD Disclosure; Other Events; Financial Statements and Exhib	7.01,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-07-31
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	33 rows · 2010 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-09-10 to 2026-10-15
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-03-27 to 2026-08-12
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Moderna, Inc. (MRNA)

Institutions holding — 12 quarters

Moderna, Inc. (MRNA)

Monthly Net Insider Flow (000 shares)

Signal Summary

Moderna, Inc. (MRNA)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding MRNA — quarterly

Institutional Put/Call — quarterly

Moderna, Inc. (MRNA)

Where MRNA Trades in the Dark

Moderna, Inc. (MRNA)

3.8 · Employees (SEC filings)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Balance Sheet — Full

Cash Flow Statement — Full

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Street Price Target — Trajectory

Third-Party Composite Rating

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Family Scores (site weights)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)

Moderna, Inc. (MRNA)